In 2025, Meddenovo Drug Design secured over €1 million in equity funding, backed by ACT Venture Partners and INVEST 101 from Türkiye Development Fund, two funds committed to supporting the next generation of science-driven technology companies. This milestone reflects growing confidence in Meddenovo’s vision to advance AI- and physics-powered drug design, with a strong focus on discovering and optimizing innovative cyclic peptide modalities.

ACT Venture Partners, a Netherlands based VC, is recognized for partnering with early-stage European deeptech founders and supporting breakthrough technologies from the earliest phases of development. With its focus on high-impact innovation at the intersection of computation and life sciences, ACT’s involvement highlights Meddenovo’s positioning within the emerging landscape of deep scientific drug discovery platforms.

Türkiye Development Fund, through its investment arm INVEST 101, supports high-potential, innovation-driven companies developing advanced technologies with strong scientific and economic impact. Its investment in Meddenovo reflects a commitment to fostering competitive deep tech ventures and accelerating the growth of research-intensive companies addressing complex technological challenges.

Together, these investments provide Meddenovo with strong strategic backing as it continues to expand the capabilities of Mexa, its AI-powered computational platform for designing cyclic peptides and other complex modalities tailored to challenging biological targets. This funding will enable Meddenovo to accelerate platform development, strengthen partnerships with leading pharmaceutical innovators, and advance its long-term vision of making de novo peptide discovery more efficient, precise, and scalable.